Abilify for Depression and Bipolar Disorder: A Meta-Analysis
The Carlat Psychiatry Report, Volume 7, Number 11, November 2009
https://www.thecarlatreport.com/newsletter-issue/tcprv7n11/
Issue Links: Learning Objectives | Editorial Information
Topics: Antipsychotics
Section editor, Glen Spielmans, PhD
Abilify (aripiprazole), which has long been FDA-approved for both schizophrenia and manic episodes of bipolar disorder, was recently approved for augmentation of antidepressants in patients with treatment-resistant depression.
You can't view details of this content, please login or buy subscription here
Section editor, Glen Spielmans, PhD
Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.